Faeth Therapeutics (FTH) Reiterated at Market Outperform by Citizens Ahead of Topline Data from Ph2 Study

October 8, 2026 4:16 AM

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $51.00 price target on Faeth Therapeutics (NASDAQ: FTH).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found